Straits Times Index
3,436.30 +20.79 (+0.61%) Nikkei
40,729.19 +148.43 (+0.37%) Hang Seng
18,008.43 +29.86 (+0.17%) FTSE 100
8,171.12 +49.92 (+0.61%) Bitcoin USD
59,008.93 -1,866.30 (-3.07%) CMC Crypto 200
1,235.69 -99.23 (-7.44%)
PCVX Aug 2024 95.000 call
| Previous close | 2.5500 |
| Open | N/A |
| Bid | 1.0000 |
| Ask | 4.6000 |
| Strike | 95.00 |
| Expiry date | 2024-08-16 |
| Day's range | 2.5500 - 2.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GuruFocus.comInsider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX)
On July 1, 2024, Jim Wassil, Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), executed a sale of 3,000 shares of the company. The transaction was documented in an SEC Filing. Following this transaction, the insider now owns 210,503 shares of Vaxcyte Inc.
GlobeNewswireVaxcyte Appoints John Furey to Board of Directors
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. “We are thrilled to welcome John to Vaxcyte’s Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, sup
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
